invest summari reiter overweight rate
pt follow modest beat introduc achiev sale
growth oper ep guidanc oper growth
acceler compar prior year guidanc impli
momentum continu think set achiev sale growth
guidanc could see upsid guidanc full launch new knee
product partial cementless revis rosa tka go better expect
come call confid suppli issu weigh growth
mostli resolv increas spend product launch sale
channel acceler top-line addit manag expect
see oper leverag eas investor concern regard
potenti spend continu believ repres attract
risk/reward opportun level
 recon market appear stabl three largest hip knee player
ow nc report result recon
market appear stabl global recon growth larg in-lin
sequenti adjust y/i comp
strong apac emea drive modest beat report solid top
line revenu organ beat factset consensu
organ growth deceler sequenti quarter
note benefit easier comp apac emea grew
ex-reb adjust respect repres emea best
perform two year report ep beat consensu
issu full year guidanc report top-lin growth
net fx headwind impli oper growth
think full launch new knee product drive top-lin acceler
lower revenu estim
ep guidanc bracket consensu despit invest earli ep
guidanc bracket consensu despit om guidanc
slightli estim due increment spend product
launch sg expect lower interest expens lower tax rate
off-set increas spend lower ep estim
lower ep estim
 valuat pt base price-to-earnings ep estim
disclosur section may found page
sourc compani document factset cantor fitzgerald estim
exhibit comparison cantor estim
compani document factset cantor fitzgerald estim
inc million except per dilut inc million except per share current priorcurr priorp growth gener adminstr incom expens tax provis dilut share februari
zbh oper issu leadership uncertainti warrant discount peer
 said think zbh valuat could quickli rebound move toward histor
averag post coupl strong quarter rebuild investor confid price target
base price-to-earnings multipl ep estim
may abl recaptur share lost meaning amount hip knee share
last two year histor share shift given year ten basi
point may abl recaptur share quickli lost
larg ou exposur subject addit risk deriv net sale
outsid zbh larg intern oper expos number addit risk
includ fx risk polit econom instabl unexpect chang foreign regulatori
requir foreign medic reimburs polici
cut effort healthcar purchas organ may materi advers effect
zbh financi result mani zbh custom form group purchas organ
effort contain cost failur respond cost-contain effort group purchas
organ could materi advers effect sale margin
fda could take addit action fda conduct recent inspect found
observ said on-track remedi plan address old new
observ anticip fda could potenti issu warn letter take
action could neg affect zbh oper
million except per share data
cost good sold
sell gener adminstr
incom incom tax
sell gener adminstr
amort intang
sell gener adminstr
compani document cantor fitzgerald research
zimmer biomet headquart warsaw indiana found becam public compani august spun
bristol-my squibb june zimmer acquir biomet deal creat current zimmer biomet pure-
play orthoped compani knee revenu hip revenu make total compani sport medicin
extrem trauma spine dental sale
